medical research model News
-
Alfa Chemistry: Custom Design Takes Organs-On-Chips to the Next Level
In a groundbreaking move to revolutionize the field of biomedical research, Alfa Chemistry recently announced the launch of its highly anticipated custom organs-on-chips service. This cutting-edge technology provides scientists and researchers with an innovative platform to study human organs in a way that was previously impossible, promising to accelerate drug discovery, reduce the need for ...
-
Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada
The Institut universitaire de cardiologie et de pneumologie de Québec–Université Laval (the Institute) recently successfully performed a first case of percutaneous tricuspid replacement. So far, only 10 patients worldwide have undergone this type of percutaneous replacement. The procedure was performed by Dr. François Dagenais, cardiac surgeon and head of the Cardiac ...
-
Creative Biostructure Supplies MagHelix™ Zebrafish Screening Platform for Drug Discovery
Creative Biostructure, a biotechnology company specialized in structural science field, applies its expertise in structural biology and membrane proteins to the drug discovery process and has established ultimate platforms for structure accelerated drug discovery. This newly established MagHelix™ Zebrafish Screening Platform is an excellent choice for building disease models and screening ...
-
21 Jun 2010: NIH-supported study finds novel pathway May open doors for new blood pressure treatments
Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal’s blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension. "The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health ...
-
TeraRecon Appoints Sinan Batman CTO
Advanced visualization and AI leader TeraRecon today announced the appointment of Sinan Batman as Chief Technology Officer, responsible for developing next-gen, AI-based advanced visualization and clinical workflow application technologies. "Sinan shares our drive for better patient outcomes and value through out-of-the-box solutions for streamlined efficiency and effectiveness," said Romesh ...
-
Arterys Arms Clinical AI Developers With a Web Platform for Medical Image Analysis to Accelerate Collaborative Research in the Fight Against COVID-19
SAN FRANCISCO, April 22, 2020 (Newswire.com) - AI researchers around the world are developing and publishing algorithms that can detect COVID-19 in medical images, including CTs and x-rays. To support the development and validation of those algorithms, Silicon Valley startup Arterys has launched its open innovation platform, the Arterys Marketplace. AI developers can publish their algorithms to ...
By Arterys Inc.
-
Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer`s Disease Therapy
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company was awarded a $3.19 million grant from the National Institute on Aging (NIA) at National Institutes of Health (NIH). The three-year SBIR/STTR Commercialization Readiness Pilot ...
-
Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
-
Study findings offer a promising new direction for organ regeneration and tissue repair
Researchers identify a novel approach to enhance tissue growth Because most human tissues do not regenerate spontaneously, advances in tissue repair and organ regeneration could benefit many patients with a wide variety of medical conditions. Now a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber/Boston Children’s Cancer and Blood ...
-
Stanford University Partners with Kheiron Medical Technologies to Pioneer Use of AI in New Areas of Oncology
Kheiron Medical Technologies today announced its new collaboration with researchers at Stanford University to design functional proof-of-concept deep learning models to solve clinical problems in novel ways, starting with Non-Hodgkin’s Lymphoma (NHL). With the collaboration, Kheiron, which has pioneered the development and deployment of artificial intelligence solutions to help radiologists ...
-
Hyperfine Partners With Madonna’s Charitable Organization, Raising Malawi, to Increase Access to High Quality Healthcare for Children
Hyperfine Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop®, today announced a partnership with Raising Malawi, which built and co-operates Malawi’s only specialized pediatric hospital, the Mercy James Centre for Paediatric Surgery & Intensive Care (MJC). Raising Malawi and Hyperfine are partnering to highlight the important research ...
By Hyperfine
-
Melbourne Awards celebrate city’s best and brightest
Lord Mayor Sally Capp said 2021’s finalists have gone above and beyond to make our city better. “We’re thrilled to recognise and celebrate the inspirational people who are making invaluable contributions to our city,” the Lord Mayor said. “It’s the people that make our city the wonderful place it is, and the Melbourne Awards finalists are a testament to our ...
-
Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital
NEW YORK and PROVIDENCE, R.I., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther” or the “Company”), a special purpose acquisition company (SPAC) has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company. The combined company will work to accelerate ...
-
Discovery of a Whole New Class of Antimalarial Drugs Which Target PfGARP and Kill Malaria Parasites
Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the symbol, “OCEA”. Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. ...
-
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AHEA has filed with the U.S. Securities and Exchange Commission ("SEC") a preliminary proxy statement ...
-
Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ
Ocean Biomedical’s innovative business model bridges the ‘bench-to-bedside’ gap by accelerating the commercialization of innovative assets from research universities and medical centers. Ocean Biomedical’s initial core portfolios in oncology, fibrosis, and infectious diseases – all based on new target discoveries enabling first-in-class drug and vaccine ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you